The U.S. Food and Drug Administration (FDA) has issued a warning to online vendors Semaspace and Gorilla Healing over consumer safety concerns, requesting them to suspend the unlawful sale of off-brand versions of a drug that is growing in popularity due to its use for weight loss.
In letters sent to both vendors on Oct. 2 before being published on Oct. 10, the agency said that there are currently only three FDA-approved semaglutide drugs available in the United States—Ozempic, Rybelsus, and Wegovy. It noted that although there are FDA-approved tirzepatide products, the active ingredient in Eli Lilly’s Mounjaro, these are only available with a prescription from a licensed practitioner.
